- Investing.com
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Metrics to compare | LUPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLUPNPeersSector | |
---|---|---|---|---|
P/E Ratio | 44.6x | 38.8x | −0.6x | |
PEG Ratio | 0.33 | 0.80 | 0.00 | |
Price/Book | 7.1x | 6.0x | 2.6x | |
Price / LTM Sales | 4.9x | 5.1x | 3.2x | |
Upside (Analyst Target) | −6.7% | 1.4% | 41.1% | |
Fair Value Upside | Unlock | −11.1% | 5.9% | Unlock |